Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial

Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial

Objective: This phase 3 study aimed to test equivalence in efficacy and safety for QL1101, a bevacizumab analogue in Chinese patients with untreated locally advanced non-squamous non-small cell lung cancer (NSCLC). Methods: Eligible patients were randomly assigned 1:1 to receive carboplatin and pacl...

Full description

Bibliographic Details
Main Authors: Tianqing Chu, Jun Lu, Minghong Bi, Helong Zhang, Wu Zhuang, Yan Yu, Jianhua Shi, Zhendong Chen, Xiaochun Zhang, Qisen Guo, Quan Liu, Huijuan Wu, Jian Fang, Yi Hu, Xiuwen Wang, Cuicui Han, Kai Li, Baohui Han
Format: Article
Language:English
Published: China Anti-Cancer Association 2021-08-01
Series:Cancer Biology & Medicine
Subjects:
biosimilar
bevacizumab
equivalence
non-squamous nsclc
clinical efficacy
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/1829

Internet

http://www.cancerbiomed.org/index.php/cocr/article/view/1829

Similar Items